Today's Low
₹ 42.00
Today's High
₹ 43.45
52 Weeks Low
₹ 23.60
52 Weeks High
₹ 48.45
Lower
₹ 33.60
Upper
₹ 50.40
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 756.2 | 734.3 | 526.8 | 372.2 | 299.5 | 243.4 | 192.0 | 157.2 | 114.6 | 96.3 | 91.1 | 89.6 |
Total Non-Current Assets | 354.3 | 335.8 | 331.4 | 291.3 | 315.7 | 342.4 | 346.3 | 366.5 | 374.4 | 393.2 | 415.0 | 457.4 |
Total Assets | 1,110.5 | 1,070.1 | 858.2 | 663.5 | 615.2 | 585.8 | 538.3 | 523.7 | 489.0 | 489.5 | 506.1 | 547.0 |
Total Current Liabilities | 321.2 | 456.5 | 403.8 | 351.4 | 339.2 | 340.1 | 324.9 | 166.6 | 127.9 | 108.1 | 102.7 | 105.0 |
Total Non-Current Liabilities | 36.9 | 35.5 | 30.1 | 28.4 | 23.4 | 20.2 | 17.8 | 57.5 | 74.0 | 84.7 | 103.9 | 122.1 |
Shareholder's Funds | 752.9 | 578.6 | 424.8 | 284.1 | 253.1 | 225.9 | 196.3 | 300.3 | 287.5 | 297.1 | 299.9 | 320.4 |
Total Liabilities | 1,110.5 | 1,070.1 | 858.2 | 663.5 | 615.2 | 585.8 | 538.3 | 523.7 | 489.0 | 489.5 | 506.1 | 547.0 |
The Industry Price to BV stands at 6.12, vs the Price to BV of 2.61, which results in a Negative aspect.
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.05, which results in a Positive aspect.
The Industry Current Ratio stands at 2.30, vs the Current Ratio of 1.06, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 0.66, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 1,417.5 | 1,546.8 | 1,188.1 | 853.1 | 768.5 | 606.5 | 595.5 | 485.1 | 400.6 | 366.9 | 325.9 | 289.3 |
Total Expenditure | 1,338.0 | 1,410.2 | 1,069.5 | 784.6 | 701.0 | 541.8 | 534.1 | 423.5 | 352.4 | 318.0 | 295.0 | 270.1 |
Operating Profit(Excl OI) | 85.7 | 156.8 | 130.6 | 78.0 | 71.2 | 68.5 | 65.1 | 62.8 | 49.6 | 50.1 | 33.8 | 20.4 |
Add: Other Income | 6.1 | 20.1 | 12.1 | 9.5 | 3.7 | 3.7 | 3.7 | 1.2 | 1.4 | 1.2 | 2.9 | 1.2 |
Operating Profit | 85.7 | 156.8 | 130.6 | 78.0 | 71.2 | 68.5 | 65.1 | 62.8 | 49.6 | 50.1 | 33.8 | 20.4 |
Less: Interest | 2.0 | 2.4 | 1.8 | 2.0 | 2.1 | 4.4 | 7.6 | 10.5 | 8.7 | 9.9 | 11.6 | 8.0 |
PBDT | 83.7 | 154.4 | 128.8 | 76.0 | 69.1 | 64.1 | 57.5 | 52.3 | 41.0 | 40.2 | 22.2 | 12.5 |
Less: Depreciation Amortization | 27.9 | 27.6 | 30.3 | 36.9 | 39.9 | 34.3 | 33.9 | 35.2 | 38.7 | 45.8 | 45.8 | 48.1 |
PBT & Exceptional Items | 55.8 | 126.7 | 98.5 | 39.1 | 29.2 | 29.8 | 23.6 | 17.1 | 2.3 | -5.6 | -23.6 | -35.6 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.4 | 0.0 | 2.9 | 3.1 | 12.0 |
Profit Before Tax | 55.8 | 126.7 | 98.5 | 39.1 | 29.2 | 29.8 | 23.6 | 12.7 | 2.3 | -2.7 | -20.5 | -23.6 |
Less: Taxation | 17.1 | 25.0 | 1.4 | 5.5 | 0.3 | 0.0 | 0.0 | -0.1 | 0.1 | 0.0 | 0.0 | 0.1 |
Profit After Tax | 38.7 | 101.7 | 97.1 | 33.6 | 28.8 | 29.8 | 23.6 | 12.8 | 2.1 | -2.8 | -20.5 | -23.6 |
Earnings Per Share | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry Dividend Yield stands at 0.59, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Growth stands at 32.49, vs the PAT Growth of 16.43, which results in a Negative aspect.
The Industry PAT Margin stands at 9.68, vs the PAT Margin of 3.94, which results in a Negative aspect.
The Industry PE Ratio stands at 42.11, vs the PE Ratio of 28.17, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 55.8 | 126.7 | 98.5 | 39.1 | 29.2 | 29.8 | 23.0 | 17.1 | 2.3 | -5.6 | -23.6 | -35.6 | -47.6 | -40.1 | -49.3 |
Tax Paid | -16.6 | -24.9 | -1.5 | -5.9 | -0.3 | 0.0 | 0.0 | 0.1 | -0.1 | 0.0 | 0.0 | -0.1 | 0.7 | 0.0 | -0.6 |
Adjustment | 27.9 | 19.5 | 32.0 | 36.6 | 40.3 | 38.6 | 41.4 | 45.7 | 47.3 | 55.8 | 56.8 | 56.0 | 54.4 | 51.7 | 54.4 |
Changes In Working Capital | 55.8 | 126.7 | 98.5 | 39.1 | 29.2 | 29.8 | 23.0 | 17.1 | 2.3 | -5.6 | -23.6 | -35.6 | -47.6 | -40.1 | -49.3 |
Cash Flow after changes in Working Capital | -74.6 | -35.3 | 52.3 | 16.9 | 17.7 | 63.4 | 40.7 | 54.3 | 50.8 | 30.6 | 30.6 | 15.1 | 10.5 | 7.1 | -2.9 |
Cash Flow from Operating Activities | -91.2 | -60.2 | 50.8 | 11.0 | 17.4 | 63.4 | 40.7 | 50.1 | 50.7 | 33.5 | 33.6 | 27.1 | 11.1 | 6.7 | -3.5 |
Cash Flow from Investing Activities | -46.5 | -31.7 | -70.4 | -12.5 | -13.1 | -26.9 | -13.6 | -27.3 | -31.6 | -0.8 | -2.8 | -3.4 | -4.1 | -4.4 | -1.4 |
Cash Flow from Financing Activities | 143.5 | 66.3 | 47.3 | 5.5 | -0.4 | -37.8 | -23.7 | -27.3 | -19.3 | -29.1 | -29.8 | -21.8 | -5.6 | -5.7 | -5.8 |
Net Cash Inflow / Outflow | 5.9 | -25.6 | 27.7 | 4.0 | 3.9 | -1.3 | 3.4 | -4.5 | -0.3 | 3.6 | 1.0 | 1.9 | 1.5 | -3.5 | -10.7 |
Opening Cash & Cash Equivalents | 15.8 | 41.4 | 13.6 | 9.6 | 5.7 | 7.0 | 3.6 | 8.8 | 9.1 | 5.5 | 4.5 | 2.6 | 1.1 | 4.6 | 15.3 |
Closing Cash & Cash Equivalent | 21.7 | 15.8 | 41.4 | 13.6 | 9.6 | 5.7 | 7.0 | 4.4 | 8.8 | 9.1 | 5.5 | 4.5 | 2.6 | 1.1 | 4.6 |
The Industry PCF RATIO stands at 24.36, vs the PCF RATIO of 38.95, which results in a Positive aspect.
The Industry PFCF Ratio stands at 25.03, vs the PFCF Ratio of -79.11, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 4,445.5 | 4,217.7 | 4,010.4 | 3,636.9 | 3,484.7 | 4,029.8 | 3,024.0 | 3,682.8 | 3,965.0 | 3,953.1 | 3,867.3 | 2,866.0 | 3,074.2 | 3,364.0 | 2,576.4 | 2,066.0 |
Total Income | 4,486.3 | 4,250.1 | 4,034.6 | 3,668.1 | 3,496.9 | 4,038.5 | 3,033.2 | 3,714.6 | 3,991.9 | 3,981.7 | 3,883.1 | 2,907.6 | 3,102.6 | 3,401.3 | 2,589.7 | 2,083.9 |
Total Expenditure | 3,939.9 | 3,881.8 | 3,749.5 | 3,481.3 | 3,279.5 | 3,740.7 | 2,878.6 | 3,496.1 | 3,643.8 | 3,532.9 | 3,428.8 | 2,562.0 | 2,776.3 | 3,046.4 | 2,310.7 | 1,877.8 |
PBIDT (Excl OI) | 505.7 | 335.9 | 260.9 | 155.6 | 205.2 | 289.1 | 145.5 | 186.7 | 321.2 | 420.3 | 438.5 | 304.0 | 297.9 | 317.5 | 265.7 | 188.3 |
Other Income | 40.7 | 32.4 | 24.2 | 31.2 | 12.2 | 8.7 | 9.1 | 31.8 | 26.9 | 28.5 | 15.8 | 41.6 | 28.4 | 37.3 | 13.3 | 17.9 |
Operating Profit | 546.4 | 368.3 | 285.1 | 186.8 | 217.4 | 297.8 | 154.6 | 218.5 | 348.1 | 448.8 | 454.3 | 345.6 | 326.3 | 354.9 | 279.0 | 206.1 |
Interest | 21.7 | 4.6 | 2.8 | 5.6 | 5.5 | 4.7 | 4.0 | 8.0 | 7.5 | -91.2 | 2.1 | -0.5 | 12.7 | 2.9 | 2.9 | 6.2 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 524.7 | 363.7 | 282.3 | 181.2 | 211.9 | 293.1 | 150.6 | 210.6 | 340.7 | 540.0 | 452.2 | 346.2 | 313.7 | 352.0 | 276.1 | 199.9 |
Depreciation | 84.5 | 76.9 | 77.1 | 69.8 | 71.9 | 70.0 | 67.6 | 68.8 | 69.3 | 71.4 | 66.9 | 69.8 | 75.6 | 76.8 | 80.6 | 86.3 |
Profit Before Tax | 440.2 | 286.8 | 205.1 | 111.4 | 140.0 | 223.1 | 83.1 | 141.7 | 271.4 | 468.6 | 385.3 | 276.4 | 238.0 | 275.2 | 195.5 | 113.6 |
Tax | 120.3 | 74.3 | 58.8 | 29.0 | 50.1 | 65.0 | 26.8 | 18.5 | 56.2 | 95.0 | 80.6 | 8.7 | 0.1 | 3.5 | 1.9 | 3.4 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 319.9 | 212.6 | 146.3 | 82.4 | 89.9 | 158.1 | 56.3 | 123.2 | 215.2 | 373.7 | 304.7 | 267.6 | 237.9 | 271.7 | 193.6 | 110.2 |
Net Profit | 319.9 | 212.6 | 146.3 | 82.4 | 89.9 | 158.1 | 56.3 | 123.2 | 215.2 | 373.7 | 304.7 | 267.6 | 237.9 | 271.7 | 193.6 | 110.2 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 1,022.3 | 1,022.3 | 1,022.3 | 1,022.3 | 1,022.3 | 1,022.3 | 998.3 | 955.6 | 899.6 | 899.6 | 899.6 | 899.6 | 899.6 | 899.6 | 899.6 | 899.6 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 0.6 | 0.4 | 0.3 | 0.2 | 0.2 | 0.3 | 0.1 | 0.3 | 0.5 | 0.8 | 0.7 | 0.6 | 0.5 | 0.6 | 0.4 | 0.3 |
Operating Profit Margin | 12.3 | 8.7 | 7.1 | 5.1 | 6.2 | 7.4 | 5.1 | 5.9 | 8.8 | 11.4 | 11.7 | 12.1 | 10.6 | 10.5 | 10.8 | 10.0 |
Net Profit Margin | 7.2 | 5.0 | 3.6 | 2.3 | 2.6 | 3.9 | 1.9 | 3.3 | 5.4 | 9.5 | 7.9 | 9.3 | 7.7 | 8.1 | 7.5 | 5.3 |
The Industry Net Sales Growth stands at 11.00, vs the Net Sales Growth of 11.00, which results in a Positive aspect.
The Industry Mcap Growth stands at 19.42, vs the Mcap Growth of -44.70, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 44.80 | 46.35 | 42.77 |
R3 | 44.20 | 44.10 | 42.39 |
R2 | 43.60 | 43.55 | 42.26 |
R1 | 42.80 | 42.70 | 42.13 |
Pivot | 42.20 | 42.15 | 42.20 |
S1 | 41.40 | 41.30 | 41.87 |
S2 | 40.80 | 40.75 | 41.74 |
S3 | 40.00 | 39.90 | 41.62 |
S4 | 39.20 | 37.95 | 41.23 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
24.08
Neutral
RSI
32.86
Neutral
ROC
-14.18
Bearish
UltimateOscillator
27.20
Bearish
Williams Indicator
-84.90
Bullish
CCI Indicator
-102.14
Bullish
MACD
-2,925.20
Bearish
Stochastic Indicator
13.49
Bullish
ATR
2.30
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
22-02-2024 | Inter alia, consider and approve the following matters: 1. To evaluate proposals for fund raising by the Company, by way of, inter-alia, issue of securities including equity shares or any other equity linked instruments or securities including nonconvertible debt instruments along with warrants and convertible securities other than warrants or any other eligible securities by way of, inter-alia, a preferential allotment or a private placement (including one or more qualified institutions placements or further public issue of equity, in accordance with the applicable provisions of the Companies Act, 2013 and its rules made thereunder and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or through any other permissible mode, in such manner, and on such terms and conditions as may be deemed appropriate by the Board of Directors, including committee thereof, in its absolute discretion, subject to the receipt of necessary approvals, including the approval of the members of the Company at general meetings or through postal ballot and such other parties including regulatory and statutory approvals as may be required; 2. The notice of Extra-Ordinary General Meeting of the Company or Postal Ballot Notice along with explanatory statement thereto, inter-alia, for seeking approval of the members of the Company in relation to the above fund-raising proposal. |
31-01-2024 | Quarterly Results |
02-11-2023 | Quarterly Results |
05-08-2023 | Quarterly Results |
16-05-2023 | Audited Results |
13-02-2023 | Quarterly Results |
10-11-2022 | Quarterly Results |
29-07-2022 | Quarterly Results |
05-05-2022 | Audited Results |
08-02-2022 | Quarterly Results Inter alia, to consider and approve: (2) Variation/alteration of preference shareholders? rights, by converting said unlisted preference shares into Compulsorily Convertible Preference Shares and issuance of Equity Shares arising on conversion thereof, subject to the approval of preference shareholders, equity shareholders and such other regulatory, statutory authority(ies), as may be required. |
11-11-2021 | Quarterly Results |
27-07-2021 | Quarterly Results |
04-05-2021 | Audited Results |
28-04-2021 | Inter-alia, to consider and approve proposals for raising of funds, through one or more modes including further public offer/ right issue/ preferential issue of equity shares/ warrants/ fully or partly convertible instruments to public, investors, indian or foreign institution(s), body corporate including overseas corporate body(ies), NRI, foreign portfolio investor(s), promoters, promoter group and/or other entities, subject to such regulatory, statutory/ other approvals, as may be required. |